UK markets open in 48 minutes

INZY Aug 2024 5.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.90000.0000 (0.00%)
As of 11:56AM EDT. Market open.
Full screen
Previous close0.9000
Open0.9000
Bid0.0000
Ask0.0000
Strike5.00
Expiry date2024-08-16
Day's range0.9000 - 0.9000
Contract rangeN/A
Volume10
Open interestN/A
  • GlobeNewswire

    Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)

    Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presentedBOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced a data presentation and sponsored symposium at the 11th International Conference on Children

  • GlobeNewswire

    Inozyme Pharma to Present at the Jefferies Global Healthcare Conference

    BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 from 12:30-12:55 pm ET. A live webcast of the presentation can be accessed from the

  • GlobeNewswire

    Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

    BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company will present recently announced topline data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (manifesting as pseudoxanthoma elastic